A new study by researchers at the University of Cambridge and the Institute of Cancer Research, London has found that current NHS breast cancer referral criteria miss 95% of women under 50 who go on to develop the disease within a decade.
The findings, published in the British Journal of Cancer, suggest that existing guidelines—which rely primarily on family history—fail to capture the majority of high-risk cases in younger women. Using a risk assessment tool called Boadicea, researchers identified eight times as many women in this age group who later developed breast cancer compared to standard referral methods.
The study analyzed data from 1,258 women under 50 in the Breast Cancer Now Generations Study (2004–2011) and concluded that current NHS criteria miss 95% of women under 50 who develop breast cancer within 10 years.
How the NHS currently screens women under 50
In England, women under 50 are not automatically eligible for breast screening unless they meet specific risk criteria set by the National Institute for Health and Care Excellence (NICE). These criteria primarily focus on inherited genetic factors, such as mutations in the BRCA1 or BRCA2 genes, and strong family history of the disease. Women who do not meet these criteria but are concerned about their risk must request a referral from their GP for a breast cancer risk assessment.
Under the current system:
- High-risk women (typically those with a lifetime risk of 30% or more) may receive annual scans, clinical exams, or genetic testing.
- Moderate-risk women (lifetime risk of 17–30%) are often offered early annual scans starting at age 40.
- Standard-risk women are not routinely screened until age 50, when they become eligible for the NHS Breast Screening Programme (which invites women aged 50–71 for mammograms every three years).
Why the current system may be failing younger women
The study highlights that 95% of breast cancer cases in women under 50 are not linked to inherited genes, meaning most high-risk individuals are not identified under the current system. Instead, lifestyle factors—such as obesity, alcohol consumption, and hormone exposure (e.g., from oral contraceptives or HRT)—play a significant role in breast cancer risk for this age group.
Researchers argue that expanding risk assessment criteria to include these factors could dramatically improve early detection. The Boadicea tool, which incorporates family history, lifestyle, reproductive history, and genetic information, was found to identify far more high-risk cases than the current NICE guidelines.
Breast cancer trends in the UK
Breast cancer remains the most common cancer in women worldwide, with about 1 in 7 women developing the disease in their lifetime. While 96% of cases occur in women over 40, the incidence in women under 50 has risen by approximately 1.4% per year over the past few decades.
Women under 40 are nearly 40% more likely to die from breast cancer than those over 40, partly because tumors in younger women tend to be more aggressive and are often detected at later stages. Early diagnosis significantly improves survival rates, with 98% of women surviving for at least five years if cancer is caught early, compared to 75% for late-stage diagnoses.
Calls for policy changes
The study’s authors are urging the NHS to revise its referral criteria to include lifestyle and hormonal factors in risk assessments for women under 50. They estimate that 26.5% of women under 50 would be classified as above-average risk if the Boadicea tool were adopted nationally.
Currently, GPs follow strict NICE guidelines when deciding whether to refer a woman for further assessment. These guidelines do not routinely consider non-genetic risk factors, which the study suggests are critical in identifying high-risk younger women.
Expert reactions
Professor Antonis Antoniou, lead researcher from the University of Cambridge, stated: “Our findings show that the current system is missing a large proportion of women who could benefit from earlier intervention. By incorporating more comprehensive risk factors, we could save lives.”
Dr. Kotryna Temcinaite, Head of Research Communications at Breast Cancer Now, added: “This study highlights a critical gap in how we identify women at higher risk of breast cancer. We urgently need to update our approach to ensure no one is left unprotected.”
NHS response
The NHS has not yet commented on whether it plans to revise its breast cancer referral guidelines. A spokesperson for NHS England stated: “We keep all our guidelines under regular review to ensure they are based on the latest evidence and best practice.”
What’s next?
The researchers are calling for further studies to validate the Boadicea tool’s effectiveness in real-world settings. If adopted, such changes could lead to earlier screenings, more targeted surveillance, and improved survival rates for younger women at high risk of breast cancer.
For now, women under 50 who are concerned about their breast cancer risk are advised to discuss their concerns with their GP, who can assess whether a risk assessment referral is appropriate under current guidelines.